Table 1.
Demographic and Clinical Characteristics of Patients With COVID-19 on Admission
| Group A (n = 6) | Group B (n = 5) | P | All Patients (n = 11) | |
|---|---|---|---|---|
| Characteristics | ||||
| Age, median (range),a,b years | 67 (46–78) | 45(29–65) | .043 | 63 (29–78) |
| Male,c n (%) | 3 (50) | 2 (40) | 1.00 | 5 (45.45) |
| Occupation, retired and farmer,c n (%) | 5 (83.33) | 1 (20) | .080 | 6 (54.55) |
| Close-contact exposure,c n (%) | .545 | |||
| Native | 3 (50) | 1 (20) | 4 (36.36) | |
| Foreign provinces | 3 (50) | 4 (80) | 7 (63.64) | |
| Symptoms,c n (%) | ||||
| Fever | 5 (83.33) | 3 (60) | .545 | 8 (72.73) |
| Cough | 5 (83.33) | 4 (80) | 1.00 | 9 (81.82) |
| Shortness of breath | 4 (66.67) | 0 (0) | .061 | 4 (36.36) |
| Sore throat | 1 (16.67) | 1 (20) | 1.00 | 2 (18.18) |
| Nausea | 2 (33.33) | 0 (0) | .455 | 2 (18.18) |
| Headache | 0 (0) | 1 (20) | .455 | 1 (9.09) |
| With chronic medical illness,c,d n (%) | 3 (50) | 0 (0) | .182 | 3 (27.27) |
| Incubation period,a,e days | 5 (3-7) | 4 (2-7) | .514 | 5 (2-7) |
| Initial treatment,c n (%) | ||||
| Oxygen therapy | 5 (83.33) | 2 (40) | .242 | 7 (63.64) |
| Antiviral treatment | 5 (83.33) | 2 (40) | .242 | 7 (63.64) |
| Glucocorticoids | 2 (50) | 0 (0) | .455 | 2 (18.18) |
| Traditional Chinese medicine | 3 (50) | 4 (80) | .545 | 7 (63.64) |
| Blood laboratory findingsa,b | ||||
| Leucocytes, ×109/L | 7.45 (2.2–10.6) | 3.93 (2.8–4.4) | .068 | 4.350 (2.2–10.6) |
| Neutrophils, ×109/L | 6.135 (1.80–9.24) | 2.34 (1.2–2.81) | .045 | 2.81 (1.20–9.24) |
| Lymphocytes, ×109/L | 0.38 (0.20–1.61) | 1.2 (0.95–1.41) | .273 | 0.96 (0.20–1.61) |
| Platelets, ×109/L | 255 (160–501) | 204 (120–257) | .273 | 212 (120–501) |
| Hemoglobin, g/L | 122 (96–163) | 140 (134–145) | .313 | 134 (96–163) |
| Prothrombin time, seconds | 12.55 (11–13) | 12.8 (11–14) | .521 | 12.70 (11–14) |
| Albumin, g/L | 30.35 (28.3–38.6) | 39.1 (36.3–42.2) | .018 | 36.3 (28.3–42.2) |
| Alanine aminotransferase, U/L | 34 (6–159) | 25 (5–114) | .361 | 30 (5–159) |
| Aspartate aminotransferase, U/L | 37.5 (17–97) | 35 (28–64) | .465 | 35 (17–97) |
| Creatine kinase, U/L | 78.5 (40–513) | 98 (39–362) | .583 | 98 (39–513) |
| Lactic acid, mmol/L | 1.98 (0.91–4.01) | 1.39 (0.94–1.79) | .068 | 1.79 (0.91–4.01) |
| Creatinine, μmol/L | 65 (43–121) | 74 (46–81) | .584 | 72 (43–121) |
| Procalcitonin, ng/mL | 0.145 (0.1–0.47) | 0.12 (0.11–0.12) | .111 | 0.12 (0.1–0.47) |
| C-reactive protein, mg/L | 78.3 (27.5–150.3) | 13.7 (1.1–18.4) | .006 | 27.50 (1.1–150.3) |
Abbreviation: COVID-19, coronavirus disease 2019.
aMann-Whitney test.
bMedian (minimum–maximum).
cFisher exact test.
dChronic medical illness, including cardiovascular and cerebrovascular diseases and endocrine system disease.
eIncubation period results indicate the potential earliest date of symptom onset (such as cough and fever).